NasdaqGS - Delayed Quote USD
PepGen Inc. (PEPG)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 4:02 PM EDT
Research Analysis
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 5 | 5 |
Avg. Estimate | -0.87 | -0.86 | -3.16 | -2.82 |
Low Estimate | -0.98 | -1.05 | -3.56 | -3.74 |
High Estimate | -0.64 | -0.62 | -2.66 | -2.16 |
Year Ago EPS | -0.98 | -0.81 | -3.3 | -3.16 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 5 | 5 |
Avg. Estimate | -- | -- | -- | 4M |
Low Estimate | -- | -- | -- | -- |
High Estimate | -- | -- | -- | 19.98M |
Year Ago Sales | -- | -- | -- | -- |
Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
---|---|---|---|---|
EPS Est. | -0.88 | -1.01 | -0.74 | -0.72 |
EPS Actual | -0.98 | -0.81 | -0.63 | -0.87 |
Difference | -0.1 | 0.2 | 0.11 | -0.15 |
Surprise % | -11.40% | 19.80% | 14.90% | -20.80% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.87 | -0.86 | -3.16 | -2.82 |
7 Days Ago | -0.87 | -0.86 | -3.16 | -2.82 |
30 Days Ago | -0.87 | -0.86 | -3.16 | -2.82 |
60 Days Ago | -0.87 | -0.86 | -3.16 | -2.82 |
90 Days Ago | -0.73 | -0.76 | -2.87 | -2.78 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | PEPG | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 11.20% | -- | -- | 3.70% |
Next Qtr. | -6.20% | -- | -- | 7.90% |
Current Year | 4.20% | -- | -- | 2.50% |
Next Year | 10.80% | -- | -- | 13.10% |
Next 5 Years (per annum) | -- | -- | -- | 11.88% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
Reiterates | HC Wainwright & Co.: Buy to Buy | 8/1/2024 |
Reiterates | Wedbush: Outperform to Outperform | 7/31/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 5/15/2024 |
Reiterates | Wedbush: Outperform to Outperform | 5/15/2024 |
Maintains | Wedbush: Outperform to Outperform | 3/7/2024 |
Reiterates | Wedbush: Outperform to Outperform | 1/30/2024 |
Related Tickers
MLYS Mineralys Therapeutics, Inc.
14.40
+3.75%
PHVS Pharvaris N.V.
21.20
-0.24%
YMAB Y-mAbs Therapeutics, Inc.
14.45
+1.76%
LYEL Lyell Immunopharma, Inc.
1.1700
-0.85%
FYB.DE Formycon AG
52.90
+1.73%
PMVP PMV Pharmaceuticals, Inc.
1.5800
-1.25%
NYKD.OL Nykode Therapeutics AS
5.29
+2.03%
VIGL Vigil Neuroscience, Inc.
3.9600
-0.75%
MGX Metagenomi, Inc.
1.9600
-1.51%
ORIC ORIC Pharmaceuticals, Inc.
9.45
+3.28%